Toyoda, Shigeru
Hashimoto, Ryota
Tezuka, Taiyo
Sakuma, Masashi
Abe, Shichiro
Ishikawa, Tetsuya
Taguchi, Isao
Inoue, Teruo
Article History
Received: 12 March 2020
Revised: 12 April 2020
Accepted: 12 April 2020
First Online: 18 May 2020
Compliance with ethical standards
:
: TI<sup>2</sup> has received honorariums from Tanabe Mitsubishi, Astrazeneca, Daiichi Sankyo, and Boehringer Ingelheim. IT has received honorariums from Tanabe Mitsubishi, Astrazeneca, Bristol-Myers Squibb, Bayer, Takeda, Daiichi Sankyo, Otsuka, MSD, Shionogi, Kowa, Sumitomo Dainippon Pharma, and NIPRO LTD. TI<sup>2</sup> and IT have received research grants from JSPS Grants-in-Aid for Scientific Research, Esai, Chugai, Astrazeneca, Bristol-Myers Squibb, Bayer, Takeda, Daiichi Sankyo, Otsuka, MSD, Boehringer Ingelheim, Teijin Pharma, Ono, Shionogi, Mitsubishi Tanabe, Kowa, Mochida, Sanwa Kagaku Kenkyusho, Sumitomo Dainippon Pharma, and NIPRO LTD. TI<sup>1</sup> has received research grants from Astellas, Abbott Vascular, Boehringer Ingelheim, Bayer, Boston Scientific, Sanwa Kagaku Kenkyusho, Teijin Pharma, Takeda, Mitsubishi Tanabe, and Medtronic. The remaining authors declare no conflicts of interest.
: The study was conducted in accordance with the Declaration of Helsinki and all local regulatory requirements. Patients were required to give informed consent before randomization. The final protocol, its amendments, and informed consent documentation were reviewed and approved by the Dokkyo Medical University review boards. Opt-out consent was accepted from each patient for the current retrospective analysis.